Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Research

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort

Authors: Maximilian Niyazi, Maya Flieger, Ute Ganswindt, Stephanie E Combs, Claus Belka

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

Purpose

Re-irradiation has been shown to be a valid option with proven efficacy for recurrent high-grade glioma patients. Overall, up to now it is unclear which patients might be optimal candidates for a second course of irradiation. A recently reported prognostic score developed by Combs et al. may guide treatment decisions and thus, our mono-institutional cohort served as validation set to test its relevance for clinical practice.

Patients and methods

The prognostic score is built upon histology, age (< 50 vs. ≥ 50 years) and the time between initial radiotherapy and re-irradiation (≤ 12 vs. > 12 months). This score was initially introduced to distinguish patients with excellent (0 points), good (1 point), moderate (2 points) and poor (3–4 points) post-recurrence survival (PRS) after re-irradiation. Median prescribed radiation dose during re-treatment of recurrent malignant glioma was 36 Gy in 2 Gy single fractions. A substantial part of the patients was additionally treated with bevacizumab (10 mg/kg intravenously at d1 and d15 during re-irradiation).

Results

88 patients (initially 61 WHO IV, 20 WHO III, 7 WHO II) re-irradiated in a single institution were retrospectively analyzed. Median follow-up was 30 months and median PRS of the entire patient cohort 7 months. Seventy-one patients (80.7%) received bevacizumab. PRS was significantly increased in patients receiving bevacizumab (8 vs. 6 months, p = 0.027, log-rank test). KPS, age, MGMT methylation status, sex, WHO grade and the Heidelberg score showed no statistically significant influence on neither PR-PFS nor PRS.

Conclusion

In our cohort which was mainly treated with bevacizumab the usefulness of the Heidelberg score could not be confirmed probably due to treatment heterogeneity; it can be speculated that larger multicentric data collections are needed to derive a more reliable score.
Appendix
Available only for authorised users
Literature
1.
Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, Belka C, la Fougère C: FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 2012,104(1):78-82. 10.1016/j.radonc.2012.04.022CrossRefPubMed
2.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009,10(5):459-466. 10.1016/S1470-2045(09)70025-7CrossRefPubMed
3.
Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C: Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 2009,185(2):113-119. 10.1007/s00066-009-1969-9CrossRefPubMed
4.
Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 2005, 5: 55. 10.1186/1471-2407-5-55PubMedCentralCrossRefPubMed
5.
Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C: Therapeutic options for recurrent malignant glioma. Radiother Oncol 2010,98(1):1-14.CrossRefPubMed
6.
Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010,28(24):3838-3843. 10.1200/JCO.2010.30.0582PubMedCentralCrossRefPubMed
7.
Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J: Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 2013,52(1):147-152. 10.3109/0284186X.2012.692882CrossRefPubMed
8.
Jenab-Wolcott J, Giantonio BJ: Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009,9(4):507-517. 10.1517/14712590902817817CrossRefPubMed
9.
Beal K, Abrey LE, Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6: 2. 10.1186/1748-717X-6-2PubMedCentralCrossRefPubMed
10.
Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, Reardon DA: A phase II study of bevacizumab plus etoposide among recurrent malignant glioma patients. Neuro-Oncology 2009,11(5):633.
11.
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2011,118(5):1302-1312.CrossRefPubMed
12.
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE 2nd, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011,103(2):371-379. 10.1007/s11060-010-0403-6PubMedCentralCrossRefPubMed
13.
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS: Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2012,107(1):155-164. 10.1007/s11060-011-0722-2PubMedCentralCrossRefPubMed
14.
Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F: Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 2012,107(2):351-358. 10.1007/s11060-011-0748-5CrossRefPubMed
15.
Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 2007,8(8):610-622.CrossRefPubMed
16.
Kil WJ, Tofilon PJ, Camphausen K: Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 2012, 7: 25. 10.1186/1748-717X-7-25PubMedCentralCrossRefPubMed
17.
Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009,75(1):156-163. 10.1016/j.ijrobp.2008.10.043PubMedCentralCrossRefPubMed
18.
Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougere C, Ertl L, Linn J, Siefert A, Belka C: Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2012,82(1):67-76. 10.1016/j.ijrobp.2010.09.002CrossRefPubMed
19.
Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M: Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 2014,117(2):337-345. Epub 2014 Feb 7 10.1007/s11060-014-1394-5CrossRefPubMed
20.
Gallego Perez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY: Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012,14(5):667-673. 10.1093/neuonc/nos070CrossRefPubMed
21.
Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D: Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 2008,89(2):205-210. 10.1007/s11060-008-9607-4CrossRefPubMed
22.
Cohen MH, Shen YL, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009,14(11):1131-1138. 10.1634/theoncologist.2009-0121CrossRefPubMed
23.
Hundsberger T, Brugge D, Putora PM, Weder P, Weber J, Plasswilm L: Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013,112(1):133-139. 10.1007/s11060-013-1044-3CrossRefPubMed
24.
Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D: Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 2005,74(2):167-171. 10.1007/s11060-004-2463-yCrossRefPubMed
25.
de Groot JF, Yung WK: Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008,14(5):279-285. 10.1097/PPO.0b013e3181867bd6CrossRefPubMed
26.
Niyazi M, Karin I, Sohn M, Nachbichler SB, Lang P, Belka C, Ganswindt U: Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Radiat Oncol 2013, 8: 287. 10.1186/1748-717X-8-287PubMedCentralCrossRefPubMed
27.
Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann KT, Combs SE, von Bueren AO, Kortmann RD, Müller K: Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 2013,8(1):161. 10.1186/1748-717X-8-161PubMedCentralCrossRefPubMed
28.
Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Busing K, Eigenbrod S, la Fougere C, Belka C: Re-irradiation in recurrent malignant glioma: prognostic value of [(18)F]FET-PET. J Neurooncol 2012,110(3):389-395. 10.1007/s11060-012-0980-7CrossRefPubMed
29.
Niyazi M, Zehentmayr F, Niemoller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M, Mortl S, Belka C: MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 2011, 6: 153. 10.1186/1748-717X-6-153PubMedCentralCrossRefPubMed
30.
Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C: Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011, 6: 115. 10.1186/1748-717X-6-115PubMedCentralCrossRefPubMed
Metadata
Title
Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort
Authors
Maximilian Niyazi
Maya Flieger
Ute Ganswindt
Stephanie E Combs
Claus Belka
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-9-128

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue

Research

Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo

Research

IMRT sparing of normal tissues in locoregional treatment of breast cancer

Research

Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer

Case report

Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases

Research

In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer

Research

VMAT planning study in rectal cancer patients